InMed Pharmaceuticals Inc
NASDAQ:INM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Changzhou Tenglong Auto Parts Co Ltd
SSE:603158
|
CN |
InMed Pharmaceuticals Inc
EPS (Diluted)
InMed Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
EPS (Diluted)
-$1
|
CAGR 3-Years
36%
|
CAGR 5-Years
43%
|
CAGR 10-Years
28%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
47%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
EPS (Diluted)
$0
|
CAGR 3-Years
64%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InMed Pharmaceuticals Inc
Glance View
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
See Also
What is InMed Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-1.9
USD
Based on the financial report for Dec 31, 2025, InMed Pharmaceuticals Inc's EPS (Diluted) amounts to -1.9 USD.
What is InMed Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
28%
Over the last year, the EPS (Diluted) growth was 83%. The average annual EPS (Diluted) growth rates for InMed Pharmaceuticals Inc have been 36% over the past three years , 43% over the past five years , and 28% over the past ten years .
